Stevenage Bioscience Catalyst (SBC) has launched a free accelerator programme to give data-focussed biotech start-ups the skills they need to get potential new drugs and therapies to market more quickly.
The programme will run from May and is aimed at supporting start-up companies working to discover new drugs. Those selected will take part in an 18-week programme during which they will have the opportunity to network and learn from experts in the pharmaceutical and biotech industries. Start-ups will be able to build their expertise in structuring deals, accessing data, intellectual property and attract funding. At the end of the programme, founders will have the chance to pitch their idea in front of leading investors and pharmaceutical experts.
Dr Sally Ann Forsyth OBE, CEO at SBC, said, “At Stevenage Bioscience Catalyst, as a not-for-profit organisation, we are committed to enabling life science companies to connect, grow and succeed at every stage of their development. We are absolutely delighted to launch this programme which will help start-ups build their expertise, supporting them to establish the funding and relationships they need to move to the next level.”
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is a world-leading science park of global significance and is located at the centre of the largest cluster of cell and gene therapy companies in Europe. Since its opening in 2012, occupier companies have secured £1.6bn in funding and it has attracted over 40 high-profile occupier businesses and world-class research organisations to Stevenage.
For more information contact: